1. Home
  2. AMTB vs TYRA Comparison

AMTB vs TYRA Comparison

Compare AMTB & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

N/A

Current Price

$29.19

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$21.05

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMTB
TYRA
Founded
1979
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
AMTB
TYRA
Price
$29.19
$21.05
Analyst Decision
Hold
Strong Buy
Analyst Count
4
15
Target Price
$31.88
★ $47.45
AVG Volume (30 Days)
282.6K
★ 1.2M
Earning Date
10-22-2026
11-04-2026
Dividend Yield
★ 1.26%
N/A
EPS Growth
★ 386.36
N/A
EPS
★ 0.97
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.20
N/A
P/E Ratio
$30.06
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$12.98
52 Week High
$30.60
$40.65

Technical Indicators

Market Signals
Indicator
AMTB
TYRA
Relative Strength Index (RSI) 47.22 41.02
Support Level $28.31 $18.66
Resistance Level $30.19 $27.00
Average True Range (ATR) 0.78 1.44
MACD -0.11 -0.15
Stochastic Oscillator 25.67 19.80

Price Performance

Historical Comparison
AMTB
TYRA

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: